{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-25-000017","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.384633+00:00","generated_at":"2026-05-28T05:40:11.615542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris exceeds FY2024 revenue guidance with $203M; Q4 positive cash flow; Recorlev up 28% sequentially","bullets":["Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).","Q4 2024 revenue projected at $60M (35% YoY growth); company generated positive cash flow in Q4.","Recorlev net revenue in Q4 anticipated to increase ~$5M or 28% sequentially, with record new starts.","Year-end cash, equivalents, and short-term investments expected to be over $71M.","Amgen terminated XeriJect license per portfolio assessment; no material impact on Xeris outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-25-000017","json":"https://secwatch.observer/filing/0001867096-25-000017.json","markdown":"https://secwatch.observer/filing/0001867096-25-000017.md","text":"https://secwatch.observer/filing/0001867096-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000017/0001867096-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000017/xers-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:40:11.615542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}